IVERIC bio Inc. (ISEE) is a biopharmaceutical company that focuses on discovering and developing novel therapies to treat ophthalmic diseases. The company's lead product candidate, Zimura, is a complement factor C5 inhibitor being developed for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) and autosomal recessive Stargardt disease (STGD1). The company also has a pipeline of other preclinical and clinical-stage candidates for the treatment of ophthalmic diseases, including gene therapies for inherited retinal diseases. IVERIC bio is headquartered in New York City and was founded in 2013.
IVERIC bio Inc. (ISEE) is a biopharmaceutical company that focuses on discovering and developing novel therapies to treat ophthalmic diseases. The company's lead product candidate, Zimura, is a complement factor C5 inhibitor being developed for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) and autosomal recessive Stargardt disease (STGD1). The company also has a pipeline of other preclinical and clinical-stage candidates for the treatment of ophthalmic diseases, including gene therapies for inherited retinal diseases. IVERIC bio is headquartered in New York City and was founded in 2013.